Propulsion of Diabetic Retinopathy Clinical Trial Pipeline as Novel and Extensive 55+ Therapies Likely to Enter in the Domain | DelveInsight
(Albany, United States) As per DelveInsight’s assessment, globally, the Diabetic Retinopathy Pipeline constitutes 50+ key companies continuously working towards developing 55+ Diabetic Retinopathy Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Diabetic Retinopathy Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Diabetic Retinopathy NDA approvals (if any), and product development activities comprising the technology, Diabetic Retinopathy collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
To explore more information on the latest breakthroughs in the Diabetic Retinopathy Pipeline treatment landscape of the report, click here @ Diabetic Retinopathy Pipeline Outlook
Key Takeaways from the Diabetic Retinopathy Pipeline Report
- DelveInsight’s Diabetic Retinopathy Pipeline analysis depicts a robust space with 50+ active players working to develop 55+ pipeline treatment therapies.
- The leading companies in the Diabetic Retinopathy Market include Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others
- Promising Diabetic Retinopathy Pipeline therapies in the various stages of development include KSI-301, Brolucizumab, RGX 314, OTT-166, OTX-TKI, Octreotide Acetate in Microspheres 20 mg, Entelon Tab. 50mg, Intravitreal aflibercept injection [IAI], Sham, ruboxistaurin, candesartan, Lucentis, Vitis vinifera extract, and others
- On July 2023, OcuTerra Therapeutics Inc. announced a study of phase 2 clinical trials for OTT166. This study will evaluate the safety and efficacy of OTT166 Ophthalmic solution in participants with Diabetic Retinopathy.
- On August 2023, Bayer announced a study of phase 2 clinical trials for Runcaciguat (BAY1101042). This Phase 2 study is conducted to investigate the safety and efficacy of runcaciguat in the treatment of diabetic retinopathy. To assess efficacy, the retinal morphology will be investigated by 7-field color fundus photography for central assessment of the diabetic retinopathy severity score, or DRSS.
Diabetic Retinopathy Overview
Diabetic retinopathy (DR) is a major complication of diabetes mellitus (DM), which remains a leading cause of visual loss in working-age populations. The retina contains photoreceptor cells that function in the process of visual transduction, i.e., transforming light signals to nerve impulses eventually transmitted from the optic nerve to the brain forming an image.
For further information, refer to the detailed Diabetic Retinopathy Unmet Needs, click here for Diabetic Retinopathy Ongoing Clinical Trial Analysis
Diabetic Retinopathy Emerging Drugs Profile
- KSI-301: Kodiak Sciences
- Brolucizumab: Novartis
- RGX 314: Regenxbio Inc.
- OTT-166: OcuTerra Therapeutics
- OTX-TKI: Ocular Therapeutix
Diabetic Retinopathy Pipeline Therapeutics Assessment
There are approx. 50+ key companies which are developing the therapies for Diabetic Retinopathy. The Diabetic Retinopathy companies which have their Diabetic Retinopathy drug candidates in the most advanced stage, i.e. phase III include, Kodiak Sciences.
Request a sample and discover the recent advances in Diabetic Retinopathy Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Diabetic Retinopathy Segmentation
Diabetic Retinopathy Drugs and Companies
- OTT166: OcuTerra Therapeutics Inc.
- MS-R001 (rapamycin): Santen Inc.
- Runcaciguat (BAY1101042): Bayer
Diabetic Retinopathy Therapeutics Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Some of the Companies in the Diabetic Retinopathy Therapeutics Market include-
Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others.
Dive deep into rich insights for drugs for the Diabetic Retinopathy Pipeline, Click here @ Diabetic Retinopathy Unmet Needs and Analyst Views
Scope of the Diabetic Retinopathy Pipeline Report
- Coverage- Global
- Diabetic Retinopathy Companies- Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others.
- Diabetic Retinopathy Pipeline Therapies- KSI-301, Brolucizumab, RGX 314, OTT-166, OTX-TKI, Octreotide Acetate in Microspheres 20 mg, Entelon Tab. 50mg, Intravitreal aflibercept injection [IAI], Sham, ruboxistaurin, candesartan, Lucentis, Vitis vinifera extract, and others
- Diabetic Retinopathy Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Diabetic Retinopathy Merger and acquisitions, Licensing Activities
Table of Content
- Introduction
- Diabetic Retinopathy Executive Summary
- Diabetic Retinopathy: Overview
- Diabetic Retinopathy Pipeline Therapeutics
- Diabetic Retinopathy Therapeutic Assessment
- Diabetic Retinopathy– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- KSI-301: Kodiak Sciences
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- RGX 314: Regenxbio Inc
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- OTX-TKI: Ocular Therapeutix
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Diabetic Retinopathy Key Companies
- Diabetic Retinopathy Key Products
- Diabetic Retinopathy- Unmet Needs
- Diabetic Retinopathy- Market Drivers and Barriers
- Diabetic Retinopathy- Future Perspectives and Conclusion
- Diabetic Retinopathy Analyst Views
- Diabetic Retinopathy Key Companies
- Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services
